JP2020505398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505398A5 JP2020505398A5 JP2019540061A JP2019540061A JP2020505398A5 JP 2020505398 A5 JP2020505398 A5 JP 2020505398A5 JP 2019540061 A JP2019540061 A JP 2019540061A JP 2019540061 A JP2019540061 A JP 2019540061A JP 2020505398 A5 JP2020505398 A5 JP 2020505398A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- halo
- independently selected
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- -1 Cyan Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/072601 | 2017-01-25 | ||
| CN2017072601 | 2017-01-25 | ||
| PCT/CN2018/073729 WO2018137593A1 (en) | 2017-01-25 | 2018-01-23 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505398A JP2020505398A (ja) | 2020-02-20 |
| JP2020505398A5 true JP2020505398A5 (enExample) | 2021-03-11 |
Family
ID=62979030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540061A Pending JP2020505398A (ja) | 2017-01-25 | 2018-01-23 | 化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10858367B2 (enExample) |
| EP (1) | EP3573956A4 (enExample) |
| JP (1) | JP2020505398A (enExample) |
| CN (1) | CN110446700A (enExample) |
| BR (1) | BR112019015278A2 (enExample) |
| CA (1) | CA3050156A1 (enExample) |
| WO (1) | WO2018137593A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102558308B1 (ko) * | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| US12319671B2 (en) * | 2019-06-06 | 2025-06-03 | Merck Sharp & Dohme Llc | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
| CN115698047A (zh) * | 2020-02-25 | 2023-02-03 | 非营利性组织佛兰芒综合大学生物技术研究所 | 富含亮氨酸的重复激酶2变构调节剂 |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| AR127470A1 (es) | 2021-10-27 | 2024-01-31 | H Lundbeck As | Inhibidores de lrrk2 |
| TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
| WO2025201511A1 (zh) * | 2024-03-29 | 2025-10-02 | 上海京新生物医药有限公司 | 吲唑衍生物及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120081609A (ko) * | 2009-09-29 | 2012-07-19 | 글락소 그룹 리미티드 | 신규 화합물 |
| EP2489663A1 (en) * | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| AU2015210593A1 (en) * | 2014-01-29 | 2016-07-07 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| US10954240B2 (en) * | 2014-09-03 | 2021-03-23 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| BR112018001303A2 (pt) * | 2015-07-23 | 2018-09-11 | Glaxosmithkline Ip Dev Ltd | ?compostos? |
| US20200002323A1 (en) * | 2017-01-25 | 2020-01-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
-
2018
- 2018-01-23 EP EP18745270.1A patent/EP3573956A4/en not_active Withdrawn
- 2018-01-23 CA CA3050156A patent/CA3050156A1/en not_active Abandoned
- 2018-01-23 US US16/480,797 patent/US10858367B2/en not_active Expired - Fee Related
- 2018-01-23 JP JP2019540061A patent/JP2020505398A/ja active Pending
- 2018-01-23 BR BR112019015278A patent/BR112019015278A2/pt not_active Application Discontinuation
- 2018-01-23 CN CN201880019059.1A patent/CN110446700A/zh active Pending
- 2018-01-23 WO PCT/CN2018/073729 patent/WO2018137593A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505398A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2018524390A5 (enExample) | ||
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2014037426A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| JP2004506736A5 (enExample) | ||
| JP2020505356A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| JP2016506959A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| JP2017537948A5 (enExample) | ||
| JP2016503785A5 (enExample) | ||
| WO2006105063A1 (en) | Heterobicylic inhibitors of tgfbeta | |
| JP2013509392A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2014520108A5 (enExample) | ||
| JP2014514290A5 (enExample) | ||
| JP2018532788A5 (enExample) | ||
| JP2021500332A5 (enExample) | ||
| RU2017112989A (ru) | Соединения и способы |